Natixis Advisors LLC Has $1.32 Million Stake in Grifols, S.A. (NASDAQ:GRFS)

Natixis Advisors LLC trimmed its stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 18.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 176,720 shares of the biotechnology company's stock after selling 38,947 shares during the quarter. Natixis Advisors LLC's holdings in Grifols were worth $1,315,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Brandes Investment Partners LP lifted its position in shares of Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock worth $152,491,000 after buying an additional 592,096 shares during the period. Fore Capital LLC bought a new position in shares of Grifols during the fourth quarter valued at $967,000. HighTower Advisors LLC lifted its holdings in shares of Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after acquiring an additional 3,936 shares during the period. Highland Peak Capital LLC boosted its stake in shares of Grifols by 29.5% in the 4th quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 179,114 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Grifols in the 4th quarter worth about $91,000.

Grifols Price Performance

Shares of GRFS traded down $0.04 on Friday, hitting $7.27. The company's stock had a trading volume of 586,558 shares, compared to its average volume of 1,231,491. The company has a market capitalization of $5.00 billion, a PE ratio of 6.21 and a beta of 0.35. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The company has a 50 day moving average price of $7.56 and a 200 day moving average price of $8.05. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley began coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.